239 related articles for article (PubMed ID: 30516547)
1. Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.
Rusznak M; Peebles RS
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):38-45. PubMed ID: 30516547
[TBL] [Abstract][Full Text] [Related]
2. Cellular interactions in aspirin-exacerbated respiratory disease.
Badrani JH; Doherty TA
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: A hypothesis.
Picado C; Mullol J; Roca-Ferrer J
J Allergy Clin Immunol; 2023 Feb; 151(2):310-313. PubMed ID: 36126795
[TBL] [Abstract][Full Text] [Related]
4. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
White AA; Doherty TA
Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
[TBL] [Abstract][Full Text] [Related]
5. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
6. Metabolic regulation by prostaglandin E
Robb CT; Zhou Y; Felton JM; Zhang B; Goepp M; Jheeta P; Smyth DJ; Duffin R; Vermeren S; Breyer RM; Narumiya S; McSorley HJ; Maizels RM; Schwarze JKJ; Rossi AG; Yao C
Allergy; 2023 Mar; 78(3):714-730. PubMed ID: 36181709
[TBL] [Abstract][Full Text] [Related]
7. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
Liu T; Kanaoka Y; Barrett NA; Feng C; Garofalo D; Lai J; Buchheit K; Bhattacharya N; Laidlaw TM; Katz HR; Boyce JA
J Immunol; 2015 Oct; 195(8):3537-45. PubMed ID: 26342029
[TBL] [Abstract][Full Text] [Related]
8. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.
Machado-Carvalho L; Martín M; Torres R; Gabasa M; Alobid I; Mullol J; Pujols L; Roca-Ferrer J; Picado C
J Allergy Clin Immunol; 2016 Jan; 137(1):99-107.e7. PubMed ID: 26560040
[TBL] [Abstract][Full Text] [Related]
9. Aspirin exacerbated respiratory disease: Current topics and trends.
Rodríguez-Jiménez JC; Moreno-Paz FJ; Terán LM; Guaní-Guerra E
Respir Med; 2018 Feb; 135():62-75. PubMed ID: 29414455
[TBL] [Abstract][Full Text] [Related]
10. Aspirin-exacerbated respiratory disease.
Wangberg H; White AA
Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease.
Laidlaw TM; Cutler AJ; Kidder MS; Liu T; Cardet JC; Chhay H; Feng C; Boyce JA
J Allergy Clin Immunol; 2014 Jun; 133(6):1692-701.e3. PubMed ID: 24486071
[TBL] [Abstract][Full Text] [Related]
12. Association of interleukin-25 levels with development of aspirin induced respiratory diseases.
Lee JU; Chang HS; Lee HJ; Bae DJ; Son JH; Park JS; Choi JS; Hwang HG; Park CS
Respir Med; 2017 Feb; 123():71-78. PubMed ID: 28137499
[TBL] [Abstract][Full Text] [Related]
13. Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.
Cahill KN; Raby BA; Zhou X; Guo F; Thibault D; Baccarelli A; Byun HM; Bhattacharyya N; Steinke JW; Boyce JA; Laidlaw TM
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):34-40. PubMed ID: 26051534
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E
Zhou Y; Wang W; Zhao C; Wang Y; Wu H; Sun X; Guan Y; Zhang Y
Front Immunol; 2018; 9():501. PubMed ID: 29593738
[TBL] [Abstract][Full Text] [Related]
15. Cysteinyl leukotriene E
Salimi M; Stöger L; Liu W; Go S; Pavord I; Klenerman P; Ogg G; Xue L
J Allergy Clin Immunol; 2017 Oct; 140(4):1090-1100.e11. PubMed ID: 28115217
[TBL] [Abstract][Full Text] [Related]
16. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
17. Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity.
Liu T; Barrett NA; Kanaoka Y; Yoshimoto E; Garofalo D; Cirka H; Feng C; Boyce JA
J Immunol; 2018 Feb; 200(3):915-927. PubMed ID: 29282304
[TBL] [Abstract][Full Text] [Related]
18. Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.
Eid R; Yan CH; Stevens W; Doherty TA; Borish L
J Allergy Clin Immunol; 2021 Aug; 148(2):309-318. PubMed ID: 34364539
[TBL] [Abstract][Full Text] [Related]
19. Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism.
Liu T; Barrett NA; Kanaoka Y; Buchheit K; Laidlaw TM; Garofalo D; Lai J; Katz HR; Feng C; Boyce JA
Mucosal Immunol; 2019 May; 12(3):679-690. PubMed ID: 30664709
[TBL] [Abstract][Full Text] [Related]
20. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
